TG Therapeutics, Inc. Announces that the GENUINE Phase 3 Study has Reached Target Enrollment
Dec 06, 2016 12:00 pm UTC| Business
NEW YORK, Dec. 06, 2016 -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that the target enrollment of 120 patients in the GENUINE Phase 3 study has been met and enrollment will be closed shortly. The GENUINE...
Automated Phishing Campaigns Increase Profits for Hackers
Dec 06, 2016 12:00 pm UTC| Business
REDWOOD SHORES, Calif., Dec. 06, 2016 -- Imperva, Inc. (NYSE:IMPV), committed to protecting business-critical data and applications in the cloud and on-premises, today released its new Hacker Intelligence Initiative...
Dec 06, 2016 12:00 pm UTC| Business
- Completed enrollment in the two lowest dose cohorts, third cohort now in progress - - Patients had on average failed 4 prior therapies - - Across the first two cohorts, 20% of patients achieved a complete...
Dec 06, 2016 12:00 pm UTC| Business
MILLIS, Mass., Dec. 06, 2016 -- The waterproof Kanguru Defender 3000™ hardware encrypted flash drive is an ideal data security device for any organization seeking to protect data on the go. Kanguru Solutions, a...
Codexis to Commercially Supply Proprietary Enzyme to Tate & Lyle
Dec 06, 2016 12:00 pm UTC| Business
REDWOOD CITY, Calif., Dec. 06, 2016 -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, today announced that it has entered into an exclusive agreement with Tate Lyle, a global provider of...
Dec 06, 2016 12:00 pm UTC| Business
-- Demonstrates Broad Activity Against Four Blood Cancers-- -- Underscores Strategic Progress on Near-Term Milestones --SAN DIEGO, Dec. 06, 2016 -- Immunomedics, Inc. (NASDAQ:IMMU) today announced that IMMU-140, the...
Dec 06, 2016 12:00 pm UTC| Business
HOUSTON, Dec. 06, 2016 -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid...